OptiVol for accurate prediction of heart failure

Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial. Results showed that Medtronic, Inc. (NYSE: MDT) OptiVol® Fluid Status Monitoring, which measures changes in fluid build up in the chest cavity, predicted 76 percent of future heart failure events as compared to only 23 percent detected by weight monitoring alone. In other words, OptiVol was three times more sensitive. FAST findings were presented as a late breaking clinical trial during the 13^th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Boston.

“This data shows that OptiVol Fluid Status Monitoring is a more accurate predictor of heart failure events than weight monitoring alone,” said William T. Abraham, M.D., professor of Medicine and Physiology, at The Ohio State University and FAST principal investigator. “Instead of relying on patients with implantable heart devices to weigh themselves daily, the standard of care should include the use of implantable fluid status monitoring technology to identify worsening heart failure before symptoms worsen and lead to hospitalization.” Heart failure hospitalizations cost $18.8 billion annually in the United States.¹

Following are key findings from FAST:

• OptiVol accurately predicted 48 of 65 heart failure events in 31 patients, which corresponds to a per patient adjusted sensitivity (some patients had more than one heart failure event) of 76 percent, whereas weight monitoring detected 13 heart failure events for a per patient adjusted sensitivity of 23 percent.
• Forty heart failure events were predicted using OptiVol, but were not detected by weight monitoring. Conversely, weight monitoring identified only five events undetected by OptiVol. Eight events were detected by both fluid and weight monitoring.
• Fluid monitoring had an unexplained detection rate of 1.9 events per patient per year as compared with 4.3 events per patient per year with weight monitoring.
• OptiVol data was available for nearly every day of follow-up on all patients in the trial, whereas daily weight data was not provided by patients for 24 percent of the follow up period.

“These compelling long-term results again demonstrate the clinical advantage and accuracy of OptiVol Fluid Status Monitoring in predicting worsening heart failure,” said Marshall Stanton M.D., vice president of clinical research for the Cardiac Rhythm Disease Management business at Medtronic. “With clinical trials enrolling more than 1,400 patients, strong clinical evidence shows that OptiVol identifies patients at significantly greater risk of worsening heart failure.”